Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EHang Holdings Ltd - ADR (EH) vs TransMedics Group Inc (TMDX) Price & Performance

EHang Holdings Ltd - ADRTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

EHang Holdings Ltd - ADR vs TransMedics Group Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.14 (market cap $309.45M), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 8.9× EHang Holdings Ltd - ADR's market cap, and TransMedics Group Inc is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and TransMedics Group Inc for 24 Days on average.

EHTMDX
Market Cap
$309.45M$2.74B
Volume
765,799949,331
Sector
IndustrialsHealth
52-Week High
$18.94$150.42
52-Week Low
$4.03$61.99
Typical Hold Time
46 Days24 Days
Enterprise Value
$261.14M$3.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EHang Holdings Ltd - ADR

EHang Holdings Limited (EH) trades at $4.14, showing no recent price movement. The stock is technically bearish with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $275.98 million on $417.98 million revenue in 2025, with negative profit margins and returns. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims.

The outlook remains challenging with persistent losses and regulatory scrutiny. Investment opportunities hinge on successful commercialization of eVTOL technology, but risks include high cash burn, negative earnings, and legal uncertainties. Analyst consensus is mixed with 20% buy, 40% hold, and 40% sell ratings, reflecting cautious sentiment.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.

The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EH
100% Buy0% Sell
Avg holding period · 46 Days
TMDX
100% Buy0% Sell
Avg holding period · 24 Days

Top news

Latest headlines on both assets

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH →

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX →